D. Boral Capital Has Lowered Expectations for Tevogen Bio (NASDAQ:TVGN) Stock Price

Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $5.00 to $2.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Tevogen Bio currently has an average rating of “Reduce” and a consensus target price of $2.00.

Tevogen Bio Stock Down 24.8%

NASDAQ:TVGN opened at $0.19 on Tuesday. The firm has a market capitalization of $37.00 million, a P/E ratio of -0.98 and a beta of -0.76. The company has a fifty day moving average of $0.31 and a 200 day moving average of $0.53. Tevogen Bio has a 52 week low of $0.17 and a 52 week high of $1.51.

Tevogen Bio’s stock is scheduled to reverse split on the morning of Friday, March 6th. The 1-50 reverse split was announced on Wednesday, March 4th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, March 5th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% during the fourth quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in Tevogen Bio by 66.7% during the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after buying an additional 33,000 shares in the last quarter.

About Tevogen Bio

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.